Ceramide C6-d7
CAT:
HY-19542S
HY-19542S
804-HY-19542S
Size:
500 μg (2.47 mM x 500 μL in Methanol)
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Ceramide C6-d7
Description:
Ceramide C6-d7 is the deuterium labeled Ceramide C6. Ceramide C6, a Ceramide pathway activator, is an exogenous short-chain ceramide which can induce apoptosis of multiple cancer cells[1][2][3].UNSPSC:
12352211Hazard Statement:
H225, H301+H311+H331, H370Target:
Apoptosis; Isotope-Labeled CompoundsType:
Isotope-Labeled CompoundsRelated Pathways:
Apoptosis; OthersField of Research:
CancerConcentration:
2.47 mM * 500 μL in MethanolPurity:
99.0Solubility:
10 mM in DMSOSmiles:
OC[C@@H]([C@@H](/C=C/CCCCCCCCCCC([2H])(C([2H])(C([2H])([2H])[2H])[2H])[2H])O)NC(CCCCC)=OMolecular Formula:
C24H40D7NO3Molecular Weight:
404.68Precautions:
H225, H301+H311+H331, H370References & Citations:
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Qiu L, et al. C6-ceramide induces salivary adenoid cystic carcinoma cell apoptosis via IP3R-activated UPR and UPR-independent pathways. Biochem Biophys Res Commun. 2020;525 (4) :997-1003.|[3]Liu L, et al. C6-ceramide treatment inhibits the proangiogenic activity of multiple myeloma exosomes via the miR-29b/Akt pathway. J Transl Med. 2020;18 (1) :298. Published 2020 Aug 3.Shipping Conditions:
Blue IceStorage Conditions:
Solution, -20°C, 2 yearsScientific Category:
Isotope-Labeled CompoundsClinical Information:
No Development ReportedCAS Number:
[2692624-22-7]
